Literature DB >> 12479278

Long-term follow up in patients receiving a small aortic valve prosthesis.

Ken-Ichi Arata1, Yoshifumi Iguro, Hiroshi Masuda, Tamahiro Kinjo, Hitoshi Matsumoto, Gouichi Yotsumoto, Ryuzo Sakata, Akira Taira.   

Abstract

BACKGROUND AND AIMS OF THE STUDY: Concern persists regarding the long-term effects of aortic valve replacement (AVR) in the small aortic root.
METHODS: Twenty-eight patients (21 females, seven males; mean age 54.1+/-11.7 years; mean body surface area (BSA) 1.39+/-0.07 m2) who underwent AVR with a 19 mm mechanical valve more than 10 years previously at the authors' institute, were followed up. Long-term echocardiographic evaluations were performed in 18 of 21 survivors.
RESULTS: Follow up in the 28 patients was complete for up to 19.2 years (mean 11.4 years); cumulative follow up was 318.1 patient-years. Actuarial survival rates at 5, 10 and 15 years were 88.5+/-6.3%, 72.0+/-9.0% and 72.0+/-9.0%, respectively. In general, NYHA class showed satisfactory improvement. Long-term echocardiography showed significant reductions in left ventricular (LV) wall thickness and mass index compared with preoperative values, despite the existence of pressure gradients. A negative correlation was found between the rate of reduction of LV wall thickness and BSA.
CONCLUSION: Implantation of the 19 mm aortic mechanical prosthesis was viable in patients with a small aortic annulus, especially if their BSA was <1.45 m2.

Entities:  

Mesh:

Year:  2002        PMID: 12479278

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  1 in total

1.  Early and mid-term outcome in terms of functional and hemodynamic performance of the st. Jude regent 19-mm aortic mechanical prosthesis versus 19-mm carpentier edwards aortic biological prosthesis.

Authors:  Edvin Prifti; Massimo Bonacchi; Fadil Ademaj; Gabriele Giunti; Giampiero Esposito; Arben Baboci; Gani Bajraktari; Altin Veshti; Aurel Demiraj; Vittorio Vanini
Journal:  J Cardiothorac Surg       Date:  2015-11-06       Impact factor: 1.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.